The mutations of Kras, Tp53, and CDKN2A have been extensively investigated and consistently shown to exert a profound impact on the survival of pancreatic cancer patients, manifesting in both early and recent clinical advancements. This evidence concerns the gene TP53 and familial pancreatic carcinoma.